Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Present And Forecasted Size Of The Phenylketonuria (PKU) Market?

The market size for phenylketonuria (PKU) has witnessed a substantial growth in recent times. It is positioned to escalate from a size of $0.85 billion in 2024 to about $0.93 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.8%. The noteworthy growth during the historic period is related to the escalation of newborn screening initiatives, enhanced awareness about metabolic disorders, dietary management of PKU, increased supply of medical food products, and official approval for PKU treatment methodologies.

Forecasts predict that the phenylketonuria (PKU) market will witness significant expansion in the coming years, swelling to a valuation of $1.29 billion by 2029. This comes with an estimated compound annual growth rate (CAGR) of 8.6%. The expected growth during the projection period can be attributed to factors like the growing acceptance of gene therapy, the proliferation of enzyme replacement therapies, increased funding for rare disease research, the escalating demand for tailor-made medicine, and governmental backing for PKU treatment coverage. Major tendencies expected during the projection period encompass the advancement of RNA-centric therapies, the incorporation of digital health solutions for managing PKU, the upsurge in cooperative efforts between biotech corporations and research entities, a focus on non-dietary therapy alternatives, and the broadening of telehealth provisions for PKU sufferers.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21257&type=smp

What Drivers Are Accelerating Expansion Of The Phenylketonuria (PKU) Market?

The surge in genetic disorder occurrences is anticipated to bolster the expansion of the phenylketonuria (PKU) market in the future. Genetic disorders are health issues stem from DNA abnormalities in a person, like gene or chromosome mutations, deletions, or duplications. The escalation in genetic disorder occurrences is credited to elements like escalating maternal age, environmental effects, advancements in diagnostic technologies, and increased awareness leading to enhanced detection rates. Phenylketonuria aids in comprehending genetic disorders by showing how inherited enzyme deficiencies can result in significant metabolic issues. For instance, as of March 2024, Gene People, a registered charity based in the UK, estimated that genetic conditions impacted 1 in 25 children, affecting more than 2.4 million children and adults in the UK. What’s more, about 30,000 newborns and children in the UK are identified with a genetic condition annually. Consequently, the surge in genetic disorder occurrences is fueling the expansion of the phenylketonuria (PKU) market.

What Are The Primary Segmentation Parameters In The Phenylketonuria (PKU) Market?

The phenylketonuria (pku)market covered in this report is segmented –

1) By Type: Hyperphenylalaninemia; Mild Phenylketonuria (PKU); Moderate And Variant; Classic Phenylketonuria (PKU)

2) By Treatment Type: Enzyme Replacement Therapy; Gene Therapy; Medication; Dietary Therapy

3) By Diagnosis: Genetic Testing; Biochemical Testing; Newborn Screening

4) By End-User: Specialty Clinics; Research Institutes; Home Healthcare; Hospitals

Subsegments:

1) By Hyperphenylalaninemia: Mild Hyperphenylalaninemia; Moderate Hyperphenylalaninemia; Severe Hyperphenylalaninemia

2) By Mild Phenylketonuria (PKU): Mild PKU with dietary management; Mild PKU with enzyme supplementation

3) By Moderate And Variant: Moderate PKU with medication; Variant PKU with treatment variations

4) By Classic Phenylketonuria (PKU): Classic PKU with strict dietary management; Classic PKU with enzyme replacement therapy

How Are Industry Trends Steering The Expansion Of The Phenylketonuria (PKU) Market?

Major companies in the phenylketonuria (PKU) market are developing innovative products using technologies like physiomimic technology to improve efficacy and safety by mimicking human physiological conditions for better drug absorption and metabolism. Physiomimic technology involves hardware, consumables, and protocols designed to replicate complex human biology and precisely predict drug responses. For example, in October 2022, Relief Therapeutics Holding SA, a Switzerland-based biopharmaceutical company, launched PKU Golike, a next-generation medical food developed with patented pharmaceutical-grade physiomimic technology for dietary management of PKU. Available as granules, packets, and bars, PKU Golike features a coating that ensures physiological amino acid absorption while masking unpleasant taste, odor, and aftertaste.

Which Players Are Shaping The Competitive Landscape Of The Phenylketonuria (PKU) Market?

Major companies operating in the phenylketonuria (PKU) market are Abbott Laboratories, Merck KGaA, Agios Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Nutricia International Private Limited, Codexis Inc., Eton Pharmaceuticals Inc., Vitaflo International Ltd., American Gene Technologies International Inc., Cambrooke Therapeutics Inc., Generation Bio Co., Mead Johnson & Company, LLC, Relief Therapeutics Holding SA, SOM Innovation Biotech S.A., Synlogic Inc., Galen Ltd, Aptatek Biosciences Inc., Homology Medicines Inc

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/phenylketonuria-pku-global-market-report

What Are The Emerging Regional Trends Driving The Phenylketonuria (PKU) Market?

North America was the largest region in the phenylketonuria (PKU) market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the phenylketonuria (PKU) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=21257&type=smp

Browse Through More Reports Similar to the Global Phenylketonuria (PKU) Market 2025, By The Business Research Company

Nasal Splints Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nasal-splints-global-market-report

Nasal Drug Delivery Technology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nasal-drug-delivery-technology-global-market-report

High Flow Nasal Cannula Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/high-flow-nasal-cannula-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model